
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : 131-I Meta-iodobenzylguanidine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
June 19, 2018
